{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T12:59:08Z","timestamp":1775566748775,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Research Special Project of National Traditional Chinese Medicine Clinical Research Base of Henan Provincial Health Commission","award":["2022JDZX101"],"award-info":[{"award-number":["2022JDZX101"]}]},{"name":"National Traditional Chinese Medicine Advantage Specialty Construction Project","award":["Guozhongyiyao Yizheng Han [2024] No. 90"],"award-info":[{"award-number":["Guozhongyiyao Yizheng Han [2024] No. 90"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-026-03976-y","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T10:24:49Z","timestamp":1772274289000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of \u03b1-blockers plus 5\u03b1-reductase inhibitors for benign prostatic hyperplasia: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"31","author":[{"given":"Rubing","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baojun","family":"Ju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zulong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"issue":"8","key":"3976_CR1","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/ajd.14359","volume":"65","author":"A Lyakhovitsky","year":"2024","unstructured":"Lyakhovitsky A, Amichai B, Galili E, Cohen A, Kridin K, Segal Z, et al. The risk of psychiatric disorders in finasteride users with benign prostatic hyperplasia and androgenetic alopecia: a population-based case-control study. Australas J Dermatol. 2024;65(8):621\u20139.","journal-title":"Australas J Dermatol"},{"issue":"3","key":"3976_CR2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.4081\/aiua.2022.3.345","volume":"94","author":"TC Bellos","year":"2022","unstructured":"Bellos TC, Tzelves LI, Manolitsis IS, Katsimperis SN, Berdempes MV, Skolarikos A, et al. Frailty and benign prostatic hyperplasia: the thrilling underlying impact. Arch Ital Urol Androl. 2022;94(3):345\u20139.","journal-title":"Arch Ital Urol Androl"},{"issue":"1","key":"3976_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10103-023-03794-2","volume":"38","author":"S Liu","year":"2023","unstructured":"Liu S, Liu H, Yao H, Sun F, Wu J, Zhou Z. A systematic review and meta-analysis of efficacy and safety comparing greenlight laser vaporization with transurethral resection of the prostate for benign prostatic hyperplasia with prostate volume less than 80 ml. Lasers Med Sci. 2023;38(1):133.","journal-title":"Lasers Med Sci"},{"issue":"9","key":"3976_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.56434\/j.arch.esp.urol.20237609.79","volume":"76","author":"M Hegazi","year":"2023","unstructured":"Hegazi M, Taverna G, Grizzi F. Is artificial intelligence the key to revolutionizing benign prostatic hyperplasia diagnosis and management? Arch Esp Urol. 2023;76(9):643\u201356.","journal-title":"Arch Esp Urol"},{"issue":"1","key":"3976_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JU.0000000000003698","volume":"211","author":"JS Sandhu","year":"2024","unstructured":"Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol. 2024;211(1):11\u20139.","journal-title":"J Urol"},{"issue":"9","key":"3976_CR6","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/iju.15518","volume":"31","author":"S Inamura","year":"2024","unstructured":"Inamura S, Terada N. Chronic inflammation in benign prostatic hyperplasia: pathophysiology and treatment options. Int J Urol. 2024;31(9):968\u201374.","journal-title":"Int J Urol"},{"issue":"1","key":"3976_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12967-023-03972-4","volume":"21","author":"J Seok","year":"2023","unstructured":"Seok J, Kwak HJ, Kwak Y, Lee M, Park KS, Kim A, et al. Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer. J Transl Med. 2023;21(1):129.","journal-title":"J Transl Med"},{"issue":"3","key":"3976_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000019706","volume":"34","author":"FM Debruyne","year":"1998","unstructured":"Debruyne FM, Jardin A, Colloi D, Resel L, Witjes WP, Delauche-Cavallier MC, et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN study group. Eur Urol. 1998;34(3):169\u201375.","journal-title":"Eur Urol"},{"issue":"1","key":"3976_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.juro.2013.01.061","volume":"190","author":"CW Fwu","year":"2013","unstructured":"Fwu CW, Eggers PW, Kaplan SA, Kirkali Z, Lee JY, Kusek JW. Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. J Urol. 2013;190(1):187\u201393.","journal-title":"J Urol"},{"issue":"3","key":"3976_CR10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/147323001204000308","volume":"40","author":"KJ Joo","year":"2012","unstructured":"Joo KJ, Sung WS, Park SH, Yang WJ, Kim TH. Comparison of \u03b1-blocker monotherapy and \u03b1-blocker plus 5\u03b1-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia. J Int Med Res. 2012;40(3):899\u2013908.","journal-title":"J Int Med Res"},{"issue":"3","key":"3976_CR11","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.juro.2008.05.004","volume":"180","author":"SA Kaplan","year":"2008","unstructured":"Kaplan SA, Roehrborn CG, McConnell JD, Meehan AG, Surynawanshi S, Lee JY, et al. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. J Urol. 2008;180(3):1030\u20132.","journal-title":"J Urol"},{"issue":"1","key":"3976_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0090-4295(02)02114-3","volume":"61","author":"RS Kirby","year":"2003","unstructured":"Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the prospective European doxazosin and combination therapy (PREDICT) trial. Urology. 2003;61(1):119\u201326.","journal-title":"Urology"},{"issue":"8","key":"3976_CR13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJM199608223350801","volume":"335","author":"H Lepor","year":"1996","unstructured":"Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med. 1996;335(8):533\u20139.","journal-title":"N Engl J Med"},{"issue":"25","key":"3976_CR14","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr., Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387\u201398.","journal-title":"N Engl J Med"},{"issue":"8","key":"3976_CR15","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/j.1742-1241.2010.02428.x","volume":"64","author":"F Montorsi","year":"2010","unstructured":"Montorsi F, Henkel T, Geboers A, Mirone V, Arrosagaray P, Morrill B, et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study. Int J Clin Pract. 2010;64(8):1042\u201351.","journal-title":"Int J Clin Pract"},{"issue":"1","key":"3976_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","volume":"57","author":"CG Roehrborn","year":"2010","unstructured":"Roehrborn CG, Siami P, Barkin J, Dami\u00e3o R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123\u201331.","journal-title":"Eur Urol"},{"issue":"1","key":"3976_CR17","doi-asserted-by":"publisher","first-page":"11116","DOI":"10.1038\/s41598-024-61977-5","volume":"14","author":"BT Yoosuf","year":"2024","unstructured":"Yoosuf BT, Panda AK, Kt MF, Bharti SK, Devana SK, Bansal D. Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis. Sci Rep. 2024;14(1):11116.","journal-title":"Sci Rep"},{"issue":"1","key":"3976_CR18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1186\/s12877-022-03415-7","volume":"22","author":"F Mansbart","year":"2022","unstructured":"Mansbart F, Kienberger G, S\u00f6nnichsen A, Mann E. Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing. BMC Geriatr. 2022;22(1):771.","journal-title":"BMC Geriatr"},{"issue":"3","key":"3976_CR19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.21037\/tau-22-690","volume":"12","author":"B Chislett","year":"2023","unstructured":"Chislett B, Chen D, Perera ML, Chung E, Bolton D, Qu LG. 5-alpha reductase inhibitors use in prostatic disease and beyond. Transl Androl Urol. 2023;12(3):487\u201396.","journal-title":"Transl Androl Urol"},{"issue":"4","key":"3976_CR20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.ucl.2025.08.001","volume":"52","author":"AE Te","year":"2025","unstructured":"Te AE, Ramaswamy A, Kaplan SA. Medical therapy for benign prostatic hyperplasia and lower urinary tract symptoms. Urol Clin North Am. 2025;52(4):595\u2013604.","journal-title":"Urol Clin North Am"},{"issue":"5","key":"3976_CR21","doi-asserted-by":"publisher","first-page":"E200","DOI":"10.25011\/cim.v40i5.28625","volume":"40","author":"D Kang","year":"2017","unstructured":"Kang D, Hu C, Fu Y, Wang D. Combination of \u03b1-blocker and 5\u03b1-reductase inhibitor for treatment of benign prostatic hyperplasia. Clin Invest Med. 2017;40(5):E200-e210.","journal-title":"Clin Invest Med"},{"issue":"6","key":"3976_CR22","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40266-025-01198-1","volume":"42","author":"J Papet","year":"2025","unstructured":"Papet J, Cornu JN, Dupuis H. Combination pharmacotherapy for benign prostatic hyperplasia: evaluation of existing literature on combination therapies for lower urinary tract symptoms associated with BPH. Drugs Aging. 2025;42(6):527\u201334.","journal-title":"Drugs Aging"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-026-03976-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-03976-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-03976-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T12:15:12Z","timestamp":1775564112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-026-03976-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3976"],"URL":"https:\/\/doi.org\/10.1186\/s40001-026-03976-y","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the data supporting our findings in this paper were freely downloaded from the public databases. No ethical approval or written informed consent for participation was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"496"}}